TrialThe Lancet. Respiratory medicine2015

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.

Birahim Pierre Ndiaye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.